{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:44:53Z","timestamp":1740167093703,"version":"3.37.3"},"reference-count":55,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T00:00:00Z","timestamp":1545350400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["5x1000n.20198."],"award-info":[{"award-number":["5x1000n.20198."]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>The updated edition of the Classification of Tumours of Haematopoietic and Lymphoid Tissues, published in September 2017 by the World Health Organization (WHO), presents many important changes to the document published in 2008. Most of these novelties are linked to the exceptional development of biomolecular techniques during the last 10 years. To illustrate how much new technologies have contributed to the better classification of single entities, as well as the discovery of new ones, would go beyond the objectives of this work. For this reason, we will take diffuse large B-cell lymphoma as an example of the cognitive improvement produced by high-yield technologies (such as the gene expression profile, the study of copy number variation, and the definition of the mutational spectrum). The acquisition of this knowledge not only has a speculative value but also represents the elements for effective application in daily practice. On the one hand, it would allow the development of personalised therapy programs, and on the other it would promote the transition from the bench of the researcher's laboratory to the patient's bedside.<\/ns4:p>","DOI":"10.12688\/f1000research.16755.1","type":"journal-article","created":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T06:30:58Z","timestamp":1545373858000},"page":"1966","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Dissecting diffuse large B-cell lymphomas of the \u201cnot otherwise specified\u201d type: the impact of molecular techniques"],"prefix":"10.12688","volume":"7","author":[{"given":"Stefano A","family":"Pileri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Derenzini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Melle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Motta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica","family":"Calleri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Antoniotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Maltoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiano","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Fiori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Tabanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2560","published-online":{"date-parts":[[2018,12,21]]},"reference":[{"key":"ref-1","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues.","volume":"2","author":"S Swerdlow","year":"2017"},{"key":"ref-2","first-page":"29-43","article-title":"Cytological and functional criteria for the classification of malignant lymphomata.","volume":"2","author":"K Lennert","year":"1975","journal-title":"Br J Cancer Suppl."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"432-4","DOI":"10.1016\/S0140-6736(82)90454-8","article-title":"U.S. National Cancer Institute working formulation of non-Hodgkin's lymphomas for clinical use.","volume":"2","author":"A Robb-Smith","year":"1982","journal-title":"Lancet."},{"key":"ref-4","doi-asserted-by":"crossref","first-page":"1361-92","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.","volume":"84","author":"N Harris","year":"1994","journal-title":"Blood."},{"key":"ref-5","article-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues.","volume":"3","author":"E Jaffe","year":"2001"},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"863-72","DOI":"10.1182\/blood-2015-02-630632","article-title":"EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment.","volume":"126","author":"A Nicolae","year":"2015","journal-title":"Blood."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"503-11","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.","volume":"403","author":"A Alizadeh","year":"2000","journal-title":"Nature."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"1002-6","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.","volume":"328","author":"R Fisher","year":"1993","journal-title":"N Engl J Med."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"1937-47","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.","volume":"346","author":"A Rosenwald","year":"2002","journal-title":"N Engl J Med."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"1094-101","DOI":"10.1038\/modpathol.2009.73","article-title":"Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.","volume":"22","author":"H Nyman","year":"2009","journal-title":"Mod Pathol."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"9991-6","DOI":"10.1073\/pnas.1732008100","article-title":"A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.","volume":"100","author":"G Wright","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"275-82","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.","volume":"103","author":"C Hans","year":"2004","journal-title":"Blood."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"5494-502","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy.","volume":"15","author":"W Choi","year":"2009","journal-title":"Clin Cancer Res."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"78-84","DOI":"10.1182\/blood-2002-04-1286","article-title":"Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma.","volume":"101","author":"L Colomo","year":"2003","journal-title":"Blood."},{"key":"ref-15","doi-asserted-by":"publisher","first-page":"714-23","DOI":"10.1002\/path.1924","article-title":"Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma.","volume":"208","author":"J Muris","year":"2006","journal-title":"J Pathol."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"200-7","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.","volume":"29","author":"P Meyer","year":"2011","journal-title":"J Clin Oncol."},{"key":"ref-17","first-page":"341-7","article-title":"Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays.","volume":"90","author":"P Zinzani","year":"2005","journal-title":"Haematologica."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"2103-13","DOI":"10.1038\/leu.2012.83","article-title":"Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.","volume":"26","author":"C Visco","year":"2012","journal-title":"Leukemia."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"805-12","DOI":"10.1200\/JCO.2006.09.4490","article-title":"Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium.","volume":"25","author":"D de Jong","year":"2007","journal-title":"J Clin Oncol."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"4836-43","DOI":"10.1182\/blood-2010-12-322362","article-title":"Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.","volume":"117","author":"G Guti\u00e9rrez-Garc\u00eda","year":"2011","journal-title":"Blood."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"1214-7","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.","volume":"123","author":"D Scott","year":"2014","journal-title":"Blood."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"2848-56","DOI":"10.1200\/JCO.2014.60.2383","article-title":"Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.","volume":"33","author":"D Scott","year":"2015","journal-title":"J Clin Oncol."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"e404-e406","DOI":"10.3324\/haematol.2017.166827","article-title":"Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay.","volume":"102","author":"J Jais","year":"2017","journal-title":"Haematologica."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"3529-37","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.","volume":"35","author":"U Vitolo","year":"2017","journal-title":"J Clin Oncol."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"272-5","DOI":"10.1111\/bjh.14556","article-title":"Lymphoma cell-of-origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts.","volume":"181","author":"G Gifford","year":"2018","journal-title":"Br J Haematol."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"2515-26","DOI":"10.1200\/JCO.2016.70.3660","article-title":"Clinical Impact of the Cell-of-Origin Classification and the MYC\/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.","volume":"35","author":"A Staiger","year":"2017","journal-title":"J Clin Oncol."},{"key":"ref-27","doi-asserted-by":"publisher","first-page":"1076-88","DOI":"10.1016\/S1470-2045(17)30444-8","article-title":"Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.","volume":"18","author":"A Chiappella","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"4015-22","DOI":"10.1200\/JCO.2016.67.2980","article-title":"Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas.","volume":"34","author":"S Cortelazzo","year":"2016","journal-title":"J Clin Oncol."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"3460-7","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.","volume":"30","author":"T Green","year":"2012","journal-title":"J Clin Oncol."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"4021-31","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.","volume":"121","author":"S Hu","year":"2013","journal-title":"Blood."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"2253-63","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.","volume":"121","author":"H Horn","year":"2013","journal-title":"Blood."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"2313-23","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas.","volume":"359","author":"G Lenz","year":"2008","journal-title":"N Engl J Med."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"1350-8","DOI":"10.1182\/blood-2011-03-345272","article-title":"Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.","volume":"118","author":"A Alizadeh","year":"2011","journal-title":"Blood."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"54-61","DOI":"10.1309\/AJCPJX4BJV9NLQHY","article-title":"The stromal cell marker SPARC predicts for survival in patients with diffuse large B-cell lymphoma treated with rituximab.","volume":"135","author":"P Meyer","year":"2011","journal-title":"Am J Clin Pathol."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"273-6","DOI":"10.1002\/ajh.23398","article-title":"CD4+ tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.","volume":"88","author":"C Keane","year":"2013","journal-title":"Am J Hematol."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"151-161","DOI":"10.20892\/j.issn.2095-3941.2017.0007","article-title":"Significance of stromal-1 and stromal-2 signatures and biologic prognostic model in diffuse large B-cell lymphoma.","volume":"14","author":"A Abdou","year":"2017","journal-title":"Cancer Biol Med."},{"key":"ref-37","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy450","article-title":"Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue.","author":"S Ciavarella","year":"2018","journal-title":"Ann Oncol."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"68-83","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.","volume":"131","author":"Z Xu-Monette","year":"2018","journal-title":"Blood."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"e555-e567","DOI":"10.1016\/S1470-2045(15)00005-4","article-title":"Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.","volume":"16","author":"C Sarkozy","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"777-83","DOI":"10.1038\/leu.2008.344","article-title":"Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC translocations.","volume":"23","author":"N Niitsu","year":"2009","journal-title":"Leukemia."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"208-17","DOI":"10.1038\/modpathol.2014.95","article-title":"B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC\/BCL2 double-hit lymphomas.","volume":"28","author":"S Li","year":"2015","journal-title":"Mod Pathol."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"2273-9","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.","volume":"114","author":"N Johnson","year":"2009","journal-title":"Blood."},{"key":"ref-43","doi-asserted-by":"publisher","first-page":"590-6","DOI":"10.1182\/blood-2017-04-737320","article-title":"How I treat double-hit lymphoma.","volume":"130","author":"J Friedberg","year":"2017","journal-title":"Blood."},{"key":"ref-44","doi-asserted-by":"publisher","first-page":"2060-4","DOI":"10.1182\/blood-2017-12-820605","article-title":"High-grade B-cell lymphoma with MYC and BCL2 and\/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.","volume":"131","author":"D Scott","year":"2018","journal-title":"Blood."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"3452-9","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.","volume":"30","author":"N Johnson","year":"2012","journal-title":"J Clin Oncol."},{"key":"ref-46","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.195958","article-title":"MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients.","author":"M Ambrosio","year":"2018","journal-title":"Haematologica."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"481-494.e15","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.","volume":"171","author":"A Reddy","year":"2017","journal-title":"Cell."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"955-62","DOI":"10.1200\/JCO.2016.71.7603","article-title":"Clinical Applications of the Genomic Landscape of Aggressive Non-Hodgkin Lymphoma.","volume":"35","author":"A Moffitt","year":"2017","journal-title":"J Clin Oncol."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"1396-407","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.","volume":"378","author":"R Schmitz","year":"2018","journal-title":"N Engl J Med."},{"key":"ref-50","doi-asserted-by":"publisher","first-page":"679-90","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.","volume":"24","author":"B Chapuy","year":"2018","journal-title":"Nat Med."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"3088-98","DOI":"10.1182\/blood-2008-01-129783","article-title":"Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.","volume":"112","author":"K Young","year":"2008","journal-title":"Blood."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"2307-19","DOI":"10.1182\/blood-2017-11-764332","article-title":"Genetics of diffuse large B-cell lymphoma.","volume":"131","author":"L Pasqualucci","year":"2018","journal-title":"Blood."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12943-015-0474-2","article-title":"Novel drug targets for personalized precision medicine in relapsed\/refractory diffuse large B-cell lymphoma: a comprehensive review.","volume":"14","author":"R Camicia","year":"2015","journal-title":"Mol Cancer."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.","volume":"8","author":"F Scherer","year":"2016","journal-title":"Sci Transl Med."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"1947-57","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy.","volume":"129","author":"D Rossi","year":"2017","journal-title":"Blood."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/7-1966\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1966\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/7-1966\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T16:58:58Z","timestamp":1573577938000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/7-1966\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,21]]},"references-count":55,"URL":"https:\/\/doi.org\/10.12688\/f1000research.16755.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.18315.r42002","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.18315.r42001","asserted-by":"subject"}]},"ISSN":["2046-1402"],"issn-type":[{"type":"electronic","value":"2046-1402"}],"subject":[],"published":{"date-parts":[[2018,12,21]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/7-1966\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.18315.r42001, Ken H Young, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Texas, USA, 21 Dec 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1966\/v1#referee-response-42001","order":0,"name":"referee-response-42001","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.18315.r42002, David M Aboulafia, Department of Hematology\/Oncology, Virginia Mason Medical Center, Washington, USA, 21 Dec 2018, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/7-1966\/v1#referee-response-42002","order":1,"name":"referee-response-42002","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"The authors\u2019 work was funded by the Italian Association for Cancer Research (AIRC), Milan; grant 5x1000 n. 20198. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}